Scientific American is part of Springer Nature, which owns or has commercial relations with thousands of scientific publications (many of them can be found at www ...
Maze Therapeutics, a kidney disease therapy developer, recently IPO-ed with a market cap of $487mn and significant early-stage investor backing. Lead asset MZE829 targets APOL1 Kidney Disease, showing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback